The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule
Introduction
Chickenpox is an infectious disease caused by the varicella-zoster virus (VZV). The reported incidence of chickenpox varies, but most studies concur that at least 90% of the population will have contracted chickenpox by the age of 15 years Preblud, 1986, Finger et al., 1994, CDC, 1996. Based on this information, it is estimated that in New Zealand more than 50,000 cases of chickenpox occur annually. In addition, an average of 128 hospitalisations and 0.8 fatalities are associated with this disease annually (New Zealand Health Information Service, 1984-1995a, New Zealand Health Information Service, 1984-1995b).
A routine varicella vaccination programme targeted at healthy children can largely prevent the morbidity and mortality associated with the varicella virus. Overseas evidence also suggests that such a programme would be cost-effective. Lieu et al. (1994) found that a routine varicella vaccine would result in net savings from a societal perspective (where the consequences of the vaccine include work loss averted due to a reduced incidence of disease). From the more restrictive perspective of health care funders, the vaccine did not save money, but was judged to be relatively cost-effective compared to other prevention programs. Varicella vaccination was added to the US immunisation schedule in 1995, with a single injection given at 12–18 months of age. Broadly comparable results to those of Lieu et al. (1994) were found by Beutels et al. (1996) in their evaluation of a varicella vaccination for German children.
New Zealand does not currently include vaccination against chickenpox on the government financed childhood immunisation schedule. The varicella vaccine is, however, available and individuals can obtain it from their general practitioners on a user-pays basis at a cost in 1997 of around NZ $62 (excluding Goods and Services Tax). The varicella vaccine approved for use in New Zealand is the Varilrix™ vaccine, an Oka-strain live attenuated vaccine. Oka-strain vaccines have a history of use in the US, Britain, Switzerland, Korea and Japan.
The aim of this study is to examine the cost-effectiveness of adding the varicella vaccine to the existing childhood immunisation schedule (Option 1), relative to a counterfactual scenario where the varicella vaccine is available on a user-pays basis (Option 2: the current New Zealand situation). Option 1 would entail the varicella vaccine being fully subsidised and administered at the same time (but as a separate injection) as the current trivalent measles, mumps and rubella vaccine (MMR), and the quadvalent diphtheria, tetanus, pertussis and haemophilus influenzae type b (DTPH) vaccines. The MMR and DTPH vaccines are administered to children at approximately 15 months of age. Research is currently being undertaken on a vaccine which would combine the varicella vaccine with the MMR, but this is unlikely to be available for another two to three years (Wells, 1996).
The modelling approach used in this study is similar to that used by Lieu et al. (1994), which facilitates comparison with these leading US results. An innovation of this paper is the inclusion of the costs and effects of varicella vaccinations received and paid for `privately' in the absence of a routine vaccination programme. These have been incorporated for two reasons. First, if the existing coverage of varicella vaccination is not acknowledged, the incremental gain in coverage and resulting cost-effectiveness of a routine programme would be over-estimated. Second, the rationale for a fully-subsidised routine programme must rest upon observations regarding the extent to which the market, left to its own devices, fails to achieve socially optimal outcomes.
The costs of vaccination and of illness caused by the VZV under both Options 1 and 2 are considered from a social perspective and include both direct health care resource use and indirect costs associated with time off paid work to care for sick children. Results are also reported from the more restrictive perspective of health care funders.
Section snippets
Methods
The cost-effectiveness analysis is based on a modelling approach to the costs and consequences of Option 1 (routine vaccination) relative to Option 2 (the existing situation). The model was developed on an Excel spreadsheet (version 5.0, Microsoft). The analysis is conducted for a 30-year period following the introduction of a routine varicella vaccination programme. The 30-year period was chosen primarily because this facilitates comparison of these results with those of Lieu et al. (1994).
Results
The incidents averted, direct costs and indirect costs for the first 30 years of a varicella programme are given in Table 4.
A varicella vaccination programme over a 30-year period could avert 852,720 cases of chickenpox including 267,750 GP visits, 1668 hospitalisations, 2 cases of long-term disability from encephalitis and 12 deaths (undiscounted). In addition, 131,000, 10,000 and 2,553,000 days of work lost from uncomplicated cases (GP visits and no treatment), hospitalised cases (including
Discussion
Introducing a routine state funded vaccination programme will result in a windfall gain to those parents that were willing and able to pay for vaccination in the absence of a programme. Using our baseline assumptions, the (undiscounted) windfall to the 10% of parents that would purchase the vaccine in the absence of a routine programme would be $359,931 annually from the introduction of a routine programme. However, in the absence of a routine programme, parents who are able to pay for the
Acknowledgements
The authors are grateful to the Department of Economics, the Department of Preventive and Social Medicine, and the Injury Prevention Research Unit, University of Otago, and the Centre for Health Economics Research and Evaluation (CHERE), University of Sydney, for support and resources provided for this research; SmithKline Beecham for providing a grant-in-aid to facilitate the involvement of the first author, the Health Research Council for the summer studentship awarded to the fourth author,
References (32)
- et al.
Epidemiologic effects of vaccines with complex direct effects in an age-structured population
Mathematical Biosciences
(1994) - et al.
The friction cost method for measuring indirect costs of disease
Journal of Health Economics
(1995) - et al.
Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies
Vaccine
(1991) On what basis should health be discounted?
Journal of Health Economics
(1993)The epidemiology of varicella-zoster virus infections
Infectious Disease Clinics of North America
(1996)- (1997)
- et al.
Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine
Pediatrics
(1994) - 3M Australia Pty Ltd and the Commonwealth of Australia, 1995. Australian National Diagnosis Related Groups (AN-DRGs)...
- et al.
Costs and benefits of routine varicella vaccination in German children
Journal of Infectious Diseases
(1996) - et al.
Productivity cost measurement through quality of life? A response to the recommendations of the Washington Panel
Health Economics
(1997)
Age-specific incidence of chickenpox
Public Health Reports
Discounting of life-saving and other non-monetary effects
Management Science
A practical guide for calculating the indirect costs of disease
PharmacoEconomics
Cited by (53)
Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: A systematic review
2021, VaccineCitation Excerpt :Use of the Oka VZV vaccine in the five-year Shingles Prevention study in 2005 (for older adults ≥ 60 years, mean follow-up of 3.1 years), saw the incidence of HZ and PHN reduced by 51.3% and 66.5% respectively compared with placebo treated patients [21,22]. Modelling studies have concluded that varicella vaccination is cost-effective from a health care payer perspective with the cost per hospitalisation averted of <$22,000 (in 2019 USD), and cost saving from societal perspective with reported benefit cost ratios of 1.3 to 3.7 [23–27]. HZ vaccination modelling studies reported that strategies could also be also cost-effective at less than $35,000 per QALY gained (2019 USD) [14,28,29].
Economic Analyses of Vaccine Policies
2017, Plotkin's VaccinesVaricella Vaccines
2017, Plotkin's VaccinesHow cost effective is universal varicella vaccination in developing countries? A case-study from Colombia
2013, VaccineCitation Excerpt :Varicella deaths are relatively more frequent in developing countries; hence, a greater cost-effectiveness is expected for these interventions. Even though the association between varicella vaccine and HZ is still in discussion, most varicella vaccination cost effectiveness studies do not include the HZ effect [41–55]. However, after a crude estimation of post-herpetic neuralgia burden costs (∼US $61 million), taking HZ population data from Spain, a 2-fold increase of HZ burden of disease after vaccination would not change cost-effectiveness.
Varicella vaccine
2012, Vaccines: Sixth EditionEconomic analyses of vaccine policies
2012, Vaccines: Sixth Edition